Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20192242 | 0.87 | PTPN1 (0.44) | PTPN1POLBNPSR1L3MBTL1KDM4E | |
| SCHEMBL4145613 | 0.84 | PTPN1 (0.55) | PTPN1POLBNPSR1L3MBTL1KDM4E | |
| SCHEMBL23185467 | 0.84 | EPHX2 (0.46) | ALDH1A1NPC1EPHX2 | |
| SCHEMBL12197944 | 0.83 | ALDH1A1 (0.60) | PTPN1POLBNPSR1L3MBTL1KDM4E | |
| SCHEMBL19116660 | 0.82 | TDP1 (0.59) | PTPN1POLBNPSR1L3MBTL1KDM4E | |
| SCHEMBL19841676 | 0.81 | PTPN1 (0.52) | PTPN1POLBNPSR1L3MBTL1KDM4E | |
| SCHEMBL24373554 | 0.81 | PTPN1 (0.52) | PTPN1POLBNPSR1L3MBTL1KDM4E | |
| SCHEMBL12932588 | 0.79 | POLB (0.53) | PTPN1POLBNPSR1L3MBTL1KDM4E | |
| SCHEMBL24663623 | 0.79 | ALDH1A1 (0.46) | POLBL3MBTL1ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL20857568 | 0.78 | DPP4 (0.46) | PTPN1KDM4EALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210187119-A1 | Drug-Conjugates, Conjugation Methods, And Uses Thereof | VIVASOR, INC. | 2021-06-24 | — | — | US | disclosed |
| US-9981046-B2 | Drug-conjugates, conjugation methods, and uses thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | SORRENTO THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9884127-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9801951-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160067350-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc, (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | ABCG2, UGT2B7, UGT1A9 | PTPN1 3211/4885POLB 4127/4885NPSR1 749/4885 |
| US-20160067350-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | PAICS, CES2, DNPEP | PTPN1 2754/4885POLB 3578/4885NPSR1 1201/4885 |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | ABCG2, UGT2B7, UGT1A9 | PTPN1 3211/4885POLB 4127/4885NPSR1 749/4885 |
| US-20210187119-A1 | Drug-Conjugates, Conjugation Methods, And Uses Thereof | PAICS, CES2, DNPEP | PTPN1 2754/4885POLB 3578/4885NPSR1 1201/4885 |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | PAICS, CES2, DNPEP | PTPN1 2754/4885POLB 3578/4885NPSR1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.